|Videos|August 31, 2022
Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
Author(s)Rafael Fonseca, MD, Luciano Costa, MD, PhD
An expert describes how he determines treatment duration and discontinuation for transplant-ineligible multiple myeloma in his clinical practice.
Advertisement
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Surgery Correlates With Better Survival Vs SABR in Early-Stage NSCLC
5